Business Description
Sotac Pharmaceuticals Ltd
ISIN : INE0O2D01012
Share Class Description:
NSE:SOTAC: Ordinary SharesTotal Employee Number:
67Compare
Compare
Traded in other countries / regions
SOTAC.India IPO Date
2023-04-13Description
Sotac Pharmaceuticals Ltd operates chiefly in pharmaceutical manufacturing, serving a broad range of therapeutic segments including anti-diabetic, anti-psychotic, vitamins and minerals, anti-cold, anti-allergic, derma products, antacids, anti-ulcerants, cardiac, analgesic, anti-bacterial, anti-fungal, and more. The company manufactures tablets, capsules, syrups, and external preparations under contract manufacturing and loan licensing agreements, for domestic and international markets. Its clients include notable pharmaceutical marketers such as Cadila Pharma and Viatris. Revenue is distributed between domestic pharmaceutical product sales and international exports, supporting scalable growth across geographies.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.03 | |||||
Equity-to-Asset | 0.44 | |||||
Debt-to-Equity | 0.64 | |||||
Debt-to-EBITDA | 2.06 | |||||
Interest Coverage | 2.01 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 2.21 | |||||
Beneish M-Score | -2.8 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 9.3 | |||||
3-Year EBITDA Growth Rate | 31 | |||||
3-Year EPS without NRI Growth Rate | 32.6 | |||||
3-Year Book Growth Rate | 44.6 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
9-Day RSI | 0.38 | |||||
14-Day RSI | 3.12 | |||||
3-1 Month Momentum % | 3.74 | |||||
6-1 Month Momentum % | 9.58 | |||||
12-1 Month Momentum % | -14.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.33 | |||||
Quick Ratio | 0.87 | |||||
Cash Ratio | 0.02 | |||||
Days Inventory | 125.56 | |||||
Days Sales Outstanding | 125.09 | |||||
Days Payable | 126.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.1 | |||||
Dividend Payout Ratio | 0.02 | |||||
Forward Dividend Yield % | 0.1 | |||||
5-Year Yield-on-Cost % | 0.1 | |||||
Shareholder Yield % | -1.78 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 33.55 | |||||
Operating Margin % | 8.57 | |||||
Net Margin % | 5.94 | |||||
EBITDA Margin % | 18.78 | |||||
FCF Margin % | 9.24 | |||||
OCF Margin % | 17.38 | |||||
ROE % | 10.31 | |||||
ROA % | 4.54 | |||||
ROIC % | 5.85 | |||||
3-Year ROIIC % | 10.19 | |||||
ROC (Joel Greenblatt) % | 13.96 | |||||
ROCE % | 17.61 | |||||
Years of Profitability over Past 10-Year | 5 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 18.22 | |||||
PE Ratio without NRI | 18.21 | |||||
Price-to-Owner-Earnings | 35.56 | |||||
PEG Ratio | 0.23 | |||||
PS Ratio | 1.08 | |||||
PB Ratio | 1.78 | |||||
Price-to-Tangible-Book | 1.91 | |||||
Price-to-Free-Cash-Flow | 11.72 | |||||
Price-to-Operating-Cash-Flow | 6.23 | |||||
EV-to-EBIT | 11.48 | |||||
EV-to-EBITDA | 8.07 | |||||
EV-to-Revenue | 1.51 | |||||
EV-to-FCF | 17.01 | |||||
Price-to-GF-Value | 0.68 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.73 | |||||
Price-to-Graham-Number | 1.24 | |||||
| Price-to-Net-Current-Asset-Value | 34.09 | |||||
Earnings Yield (Greenblatt) % | 8.71 | |||||
FCF Yield % | 8.54 | |||||
Forward Rate of Return (Yacktman) % | 12.77 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sotac Pharmaceuticals Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 970.737 | ||
| EPS (TTM) (₹) | 5.22 | ||
| Beta | 1.0181 | ||
| 3-Year Sharpe Ratio | -0.13 | ||
| 3-Year Sortino Ratio | -0.18 | ||
| Volatility % | 39.53 | ||
| 14-Day RSI | 3.12 | ||
| 14-Day ATR (₹) | 1.046156 | ||
| 20-Day SMA (₹) | 103.9275 | ||
| 12-1 Month Momentum % | -14.52 | ||
| 52-Week Range (₹) | 95.1 - 139.65 | ||
| Shares Outstanding (Mil) | 11.05 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sotac Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sotac Pharmaceuticals Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| INR 0.100000 Cash Dividend | 2025-09-19 | 121.80 (-0.57%) |
Show
Entries
Sotac Pharmaceuticals Ltd Frequently Asked Questions
What is Sotac Pharmaceuticals Ltd(NSE:SOTAC)'s stock price today?
The current price of NSE:SOTAC is ₹95.10. The 52 week high of NSE:SOTAC is ₹139.65 and 52 week low is ₹95.10.
When is next earnings date of Sotac Pharmaceuticals Ltd(NSE:SOTAC)?
The next earnings date of Sotac Pharmaceuticals Ltd(NSE:SOTAC) is .
Does Sotac Pharmaceuticals Ltd(NSE:SOTAC) pay dividends? If so, how much?
The Dividend Yield %  of Sotac Pharmaceuticals Ltd(NSE:SOTAC) is 0.1% (As of Today), Highest Dividend Payout Ratio of Sotac Pharmaceuticals Ltd(NSE:SOTAC) was 0.02. The lowest was 0.02. And the median was 0.02. The  Forward Dividend Yield % of Sotac Pharmaceuticals Ltd(NSE:SOTAC) is 0.1%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Sotac Pharmaceuticals Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers